• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Current status and future opportunities for controlling acromegaly.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Melmed, Shlomo
    Vance, Mary Lee
    Barkan, Ariel L
    Bengtsson, B A
    Kleinberg, David L
    Klibanski, Anne
    Trainer, Peter J
    Affiliation
    Division of Endocrinology and Metabolism, Ceder-Sinai Medical Center, Los Angeles, CA 90048, USA. shlomo.melmed@cshs.org
    Issue Date
    2002
    
    Metadata
    Show full item record
    Abstract
    Growth-hormone (GH) secreting adenomas, including acromegaly, account for approximately one-sixth of all pituitary adenomas and are associated with mortality rates at least twice that of the general population. The ultimate goal of therapy for acromegaly is normalization of morbidity and mortality rates achieved through removal or reduction of the tumor mass and normalization of insulin-like growth factor I (IGF-I) levels. Previously published efficacy results of current treatment modalities (surgery, conventional radiation, and medical therapy with dopamine agonists and somatostatin analogs) are often difficult to compare because of the different criteria used to define cure (some of which are now considered inadequate). For each of these modalities, pooled data from a series of acromegaly studies were reviewed for rates of IGF-I normalization, a currently accepted definition of cure. The results showed overall cure rates of approximately 10% for bromocriptine, 34% for cabergoline, 36% for conventional radiation, 50-90% for surgery for microadenomas and less than 50% for macroadenomas, and 54-66% for octreotide. These cure rates based on IGF-I normalization are generally less than those reported for cure based solely on GH levels. Novel new therapies for acromegaly include the somatostatin analog, lanreotide, Gamma Knife radiosurgery, and pegvisomant, the first in its class of new GH receptor antagonists. Although it does not appear that Gamma Knife radiosurgery results in significantly higher cure rates or fewer complications, it does provide a notable improvement in delivery compared with conventional radiation. Early studies have reported IGF-I normalization in 48% of lanreotide-treated patients and up to 97% of pegvisomant-treated.
    Citation
    Current status and future opportunities for controlling acromegaly. 2002, 5 (3):185-96 Pituitary
    Journal
    Pituitary
    URI
    http://hdl.handle.net/10541/82056
    DOI
    10.1023/A:1023369317275
    PubMed ID
    12812311
    Language
    en
    ISSN
    1386-341X
    ae974a485f413a2113503eed53cd6c53
    10.1023/A:1023369317275
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Diagnosis and treatment of pituitary adenomas.
    • Authors: Chanson P, Salenave S
    • Issue date: 2004 Dec
    • Pharmacological management of acromegaly: a current perspective.
    • Authors: Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR
    • Issue date: 2010 Oct
    • The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.
    • Authors: Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM
    • Issue date: 1998 Nov
    • How effective are current therapies for acromegaly?
    • Authors: Freda PU
    • Issue date: 2003 Aug
    • Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    • Authors: Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R
    • Issue date: 2006 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.